期刊
CANCER IMMUNOLOGY RESEARCH
卷 10, 期 7, 页码 800-810出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-21-1050
关键词
-
资金
- GBM Translational Center of Excellence
- Templeton Family Initiative in Neuro-Oncology
- Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund
- Neurosurgery Research and Education Foundation
- NIH [CA016520, CA210944, AI149680, AI155577, AI108545, AI082630]
- Parker Institute for Cancer Immunotherapy
- [R01-CA197916]
The study found that T cells in the perivascular regions of recurrent GBM were enriched and activated, and their presence was associated with outcomes, indicating that these T cells may be potential therapeutic targets.
Glioblastoma (GBM) is an immunologically cold tumor characterized by poor responsiveness to immunotherapy. Stan-dard of care for GBM is surgical resection followed by chemo-radiotherapy and maintenance chemotherapy. However, tumor recurrence is the norm, and recurring tumors are found fre-quently to have acquired molecular changes (e.g., mutations) that may influence their immunobiology. Here, we compared the immune contexture of de novo GBM and recurrent GBM (rGBM) using high-dimensional cytometry and multiplex IHC. Although myeloid and T cells were similarly abundant in de novo and rGBM, their spatial organization within tumors differed and was linked to outcomes. In rGBM, T cells were enriched and activated in perivascular regions and clustered with activated macrophages and fewer regulatory T cells. Moreover, a higher expression of phosphorylated STAT1 by T cells in these regions at recurrence was associated with a favorable prognosis. Together, our data identify differences in the immunobiology of de novo GBM and rGBM and identify perivascular T cells as potential therapeutic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据